Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
AssigneeAlexion Pharmaceuticals, Inc.
InventorsUma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
Life of this patent
Estimating the term…
Abstract
The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Claims14
A unit dose formulation comprising a pharmaceutically acceptable carrier and from about 10 milligrams to about 2 grams of a two chain polypeptide comprising the amino acid sequence of SEQ ID NO. 13 or a polypeptide having at least 80% homology to SEQ ID NO. 13.
6-9. (canceled)
A unit dose formulation for administration to a subject undergoing anticoagulant therapy with a factor Xa inhibitor, said formulation comprising a pharmaceutically acceptable carrier and a neutralizing amount of a two chain polypeptide comprising the amino acid sequence of SEQ ID NO. 13 or a polypeptide having at least 80% homology to SEQ ID NO. 13, such that the neutralizing amount is at least about a 1:1 molar ratio of circulating concentration of polypeptide over circulating concentration of the factor Xa inhibitor for a period of at least about 30 minutes.
15-19. (canceled)
21-31. (canceled)
Dependencies are inferred from the claim text.